Skip to main content
Premium Trial:

Request an Annual Quote

Zyomyx Seeks to Rise from the Ashes as Tech-Development Company

NEW YORK, Nov. 16 (GenomeWeb News) - Protein array pioneer Zyomyx today announced a new business strategy built on alliances, breaking its month-long silence after reports of massive lay-offs and an auction of much of its equipment.

 

Instead of bringing its own products to market, the company will now seek to develop products and technologies on behalf of partners. Zyomyx will focus on proteomics, molecular diagnostic, medical devices, and other industrial applications of its expertise.

 

The company will also continue to offer existing protein array products through a "streamlined service model."

 

"Our expertise and intellectual property in protein chip technologies, bio-interfaces and micro-scale bio-analysis are substantial, and we intend to accelerate the process already underway of building alliances with partners and customers to apply" these technologies, Peter Wagner, the company's new CEO and former chief technology officer, said in a statement.

 

Zyomyx did acknowledge an auction of "surplus" equipment and a "new lean structure" but did not mention lay-offs specifically in its statement.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.